Akanda Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Akanda's earnings have been declining at an average annual rate of -53.9%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 6.2% per year.
Belangrijke informatie
-53.9%
Groei van de winst
-20.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | -6.2% |
| Rendement op eigen vermogen | -696.7% |
| Nettomarge | -1,269.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Akanda geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -32 | 5 | 0 |
| 31 Mar 24 | 2 | -32 | 6 | 0 |
| 31 Dec 23 | 2 | -32 | 6 | 0 |
| 30 Sep 23 | 3 | -24 | 10 | 0 |
| 30 Jun 23 | 3 | -12 | 13 | 0 |
| 31 Mar 23 | 3 | -10 | 17 | 0 |
| 31 Dec 22 | 3 | -8 | 20 | 0 |
| 30 Jun 22 | 0 | -7 | 15 | 0 |
| 31 Mar 22 | 0 | -7 | 10 | 0 |
| 31 Dec 21 | 0 | -2 | 3 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
Kwaliteitswinsten: AKAN is currently unprofitable.
Groeiende winstmarge: AKAN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AKAN is unprofitable, and losses have increased over the past 5 years at a rate of 53.9% per year.
Versnelling van de groei: Unable to compare AKAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AKAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: AKAN has a negative Return on Equity (-696.7%), as it is currently unprofitable.